Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 23%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is projected to have a firm value of $33B with an estimated price per share of $130 based on a discounted cash flow (DCF)-based valuation approach and projected financial metrics. The company's risks include negative data for certain drugs, slower market uptake, failure to advance other programs in a timely manner, and regulatory and commercial risks. However, recent data presented for BNT326 and pumitamig in multiple subgroups of NSCLC patients support the ongoing Phase 1b/2 trials evaluating their combination, thus providing a positive outlook on the company's progress in the oncology space.

Bears say

BioNTech is a Germany-based biotechnology company with a negative outlook due to concerns surrounding its pipeline and competitive risks. While the company's Phase 3 PRESERVE-003 trial results show promise, uncertainty around confirmatory Phase 3 enrollment and FDA approval for its oncology drugs could impact potential revenue generation. Furthermore, BioNTech's reliance on its Pfizer-partnered covid vaccine for commercial success could pose a risk, as alternative brands with greater efficacy or ease of use may emerge. With multiple factors potentially hindering revenue projections, investors should approach BioNTech's stock with caution.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $128, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $128, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.